A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic… | ScholarDeck

Paper

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

New research · Neurology

Journal of neurointerventional surgery · 4w

StudyJournal of neurointerventional surgery· Aug 2026

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

Lee-Anne Slater, Laetitita de Villiers, Adam S Arthur … David Fiorella

Read paper

NeurologyStudyQ1IF 4.6

NeoCast embolization achieved 89% average devascularization of brain tumors before surgery.

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

Lee-Anne Slater … David Fiorella

Journal of neurointerventional surgery · Aug 2026 · Q1 in Neurology

Background

NeoCast TM is a solvent-free, non-adhesive biomaterial engineered to achieve microvascular occlusion.

Methods

EMBO-01 was an open-label, multicenter, prospective, externally monitored, and core lab adjudicated clinical trial.

Results

89±7%

most of each tumor's blood supply was cut off before surgery

More results

NeoCast achieved occlusion in all targeted vessels for all subjects.

There were no adverse events or device deficiencies during embolization.

The average NeoCast injection volume was 0.68±0.28 mL with an average injection time of 7.8±6.4 min.

More results

Tumor resection was complete in all subjects, with an average estimated blood loss of 240±164 mL and average total surgery time of 167±75 min.

“

Conclusion

This first-in-human study provides evidence that NeoCast can be used to reproducibly and safely achieve substantial preoperative devascularization of brain tumors supplied by the middle meningeal artery.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Review

“Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.”

Cohort Study

45 minutes

brain blood-flow monitoring found no abnormalities after visual symptoms

Case Report

“The importance of timely recognition of optic neuropathy as a complication of amiodarone and dronedarone treatment may enable discontinuing the drug, thus preventing permanent vision loss.”

Review

“The following review will examine retinal changes that are suggested as possible biomarkers for Alzheimer's disease and discuss directions for future research in the field.”

Case-control

91%

this diameter correctly identifies most patients with HIE

Case Report

9 years

time from uveitis diagnosis to multiple sclerosis diagnosis

Cohort Study

54.8%

more than half of neonates with encephalopathy lacked traditional acidemia criteria

Cohort Study

8 weeks

half took longer than 2 months to reach a surgical decision